Ozempic is a GLP-1 receptor agonist licensed for type 2 diabetes, not weight management in the UK
Its effortless
Commercial plans like Blue Cross Blue Shield of Massachusetts plan to eliminate coverage of GLP-1s for weight loss in 2026 in response to high drug costs and their effect on insurance premiums
There have also been numerous reports of Ozempic mental health side effects, such as depression or suicidal thoughts
Ostadrahimi, A., Taghizadeh, A., Mobasseri, M., Farrin, N., Payahoo, L., & Beyramalipoor Gheshlaghi, Z
Legal status complicates everything